
Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million
11/5/2026
0:00
2:27
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.
More episodes from "Pharmaceutical Executive"



Don't miss an episode of “Pharmaceutical Executive” and subscribe to it in the GetPodcast app.








